10081004Disruptive diagnostic for bacterial infection directly from whole blood in patients with SEPSISClosedEU-FundedHorizon Europe GuaranteeSepsis is the leading cause of hospital death with ~700K EU deaths annually. To treat a sepsis infection, we must identify the causative pathogens and determine their antibiotic susceptibility. However, existing blood culture testing is slow (days) and sepsis kills quickly (hours). Clinicians therefore initiate treatment with broad-spectrum antibiotics. These are sub-optimal and can be harmful to some patients. Initiation of treatment without diagnostic results also leads to overuse of antibiotics, impacting antimicrobial resistance. Many have sought to address this challenge using direct from-blood (DfB) test methods, but have failed to address the real market need. SepsiSTAT is the world’s first DfB diagnostic platform able to deliver a credible alternative to blood culture testing, but with results in hours and not days. This enables a rapid targeting of antibiotic treatments with improved patient outcomes, greater healthcare efficiencies and reduced antibiotic use.